Nothing Special   »   [go: up one dir, main page]

SG11202103586UA - Human amylin analog polypeptides and methods of use - Google Patents

Human amylin analog polypeptides and methods of use

Info

Publication number
SG11202103586UA
SG11202103586UA SG11202103586UA SG11202103586UA SG11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA SG 11202103586U A SG11202103586U A SG 11202103586UA
Authority
SG
Singapore
Prior art keywords
methods
human amylin
amylin analog
analog polypeptides
polypeptides
Prior art date
Application number
SG11202103586UA
Inventor
William Blackwell
Ved Srivastava
James Way
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of SG11202103586UA publication Critical patent/SG11202103586UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202103586UA 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use SG11202103586UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11
PCT/US2019/055696 WO2020077129A1 (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Publications (1)

Publication Number Publication Date
SG11202103586UA true SG11202103586UA (en) 2021-05-28

Family

ID=68393080

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103586UA SG11202103586UA (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Country Status (14)

Country Link
US (1) US12018059B2 (en)
EP (1) EP3864031A1 (en)
JP (1) JP2022504596A (en)
KR (1) KR20210091705A (en)
CN (1) CN113195524A (en)
AR (1) AR116632A1 (en)
AU (1) AU2019357621A1 (en)
BR (1) BR112021006823A2 (en)
CA (1) CA3116023A1 (en)
IL (1) IL282079A (en)
MX (1) MX2021004185A (en)
SG (1) SG11202103586UA (en)
TW (1) TW202028228A (en)
WO (1) WO2020077129A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158116A1 (en) * 2020-04-20 2023-05-25 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
HUE062560T2 (en) * 2020-09-24 2023-11-28 Gubra Aps Ham15-52 analogues with improved amylin receptor (hamy3r) potency
TW202400632A (en) 2021-03-03 2024-01-01 美商美國禮來大藥廠 Long-acting amylin receptor agonists and uses thereof
CN113880935B (en) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 Preparation method of Somaloutide full-protection peptide resin and preparation method of Somaloutide

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
JP3618750B2 (en) 1993-08-09 2005-02-09 ソシエテ ドゥ コンセイユ ドゥ ルシェルシュ エ ダプリカシオン サイエンティフィク，エス．アー．エス． Peptide derivatives with therapeutic effects
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
CN100506311C (en) 1996-02-02 2009-07-01 精达制药公司 Sustained delivery of an active agent using an implantable system
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
JP4215188B2 (en) 1997-12-22 2009-01-28 インターシア セラピューティクス，インコーポレイティド Rate-regulating membranes for devices that regulate drug delivery
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ES2273427T3 (en) 1997-12-30 2007-05-01 Alza Corporation SUPPLY SYSTEM OF A BENEFICIENT AGENT WITH A SHUTTER MEMBRANE.
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
PT1140014E (en) 1998-12-31 2003-07-31 Alza Corp OSMOTICAL DISTRIBUTION SYSTEM THAT HAS BOTTLE WITH EFFECTIVE USE OF SPACE
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
PT1180121E (en) 1999-05-17 2004-03-31 Conjuchem Inc LONG-TERM INSULINOTROPIC PEPTIDES
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DK1328256T3 (en) 1999-12-21 2006-02-20 Alza Corp Valve for osmotic devices
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
CA2412004C (en) 2000-06-16 2010-12-21 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2005506956A (en) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー Long-acting GLP-1 formulation
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
BR0212080A (en) 2001-08-23 2006-04-04 Lilly Co Eli glp-1 compound, method of glp-1 receptor stimulation in an individual in need of such stimulation, and use of a glp-1 compound
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
ATE376854T1 (en) 2002-06-26 2007-11-15 Alza Corp MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS
US8168233B2 (en) 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
KR20140011431A (en) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. Hybrid polypeptides with selectable properties
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5252435B2 (en) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス Amylin derivatives
ES2351527T3 (en) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc TWO-PIECE FLOW MODULATOR WITH INTERNAL DUCT FOR AN OSMOTIC ADMINISTRATION SYSTEM.
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2340261B1 (en) * 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
AU2010206614B2 (en) 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
CN102369018B (en) 2009-03-12 2016-08-03 关键生物科学有限公司 Diabetes and the treatment of metabolism syndrome
MX336323B (en) 2010-04-15 2016-01-15 Genentech Inc Anti-polyubiquitin antibodies and methods of use.
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc Long duration dual hormone conjugates
ES2664509T3 (en) 2011-06-10 2018-04-19 Novo Nordisk A/S Pramlintide derivatives
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
CN106132985B (en) 2014-04-07 2020-10-13 诺和诺德股份有限公司 Double acylated GLP-1 compounds
EP3189071B1 (en) 2014-09-04 2021-07-28 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
EA035791B1 (en) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Amylin analogues
AR109514A1 (en) 2016-09-09 2018-12-19 Zealand Pharma As AMILINE ANALOGS

Also Published As

Publication number Publication date
US20200115430A1 (en) 2020-04-16
AR116632A1 (en) 2021-05-26
WO2020077129A1 (en) 2020-04-16
CA3116023A1 (en) 2020-04-16
BR112021006823A2 (en) 2021-07-27
CN113195524A (en) 2021-07-30
US12018059B2 (en) 2024-06-25
AU2019357621A1 (en) 2021-05-27
IL282079A (en) 2021-05-31
TW202028228A (en) 2020-08-01
MX2021004185A (en) 2021-09-08
EP3864031A1 (en) 2021-08-18
JP2022504596A (en) 2022-01-13
KR20210091705A (en) 2021-07-22

Similar Documents

Publication Publication Date Title
GB2595606B (en) CRISPR-Cas effector polypeptides and methods of use thereof
IL272085A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
SG11202011308VA (en) Activatable cytokine polypeptides and methods of use thereof
IL272332A (en) Antigen-presenting polypeptides and methods of use thereof
IL297617B1 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
IL282079A (en) Human amylin analog polypeptides and methods of use
EP3538561A4 (en) Variant rna-guided polypeptides and methods of use
IL261401A (en) T-cell modulatory multimeric polypeptides and methods of use thereof
IL262403A (en) T-cell modulatory multimeric polypeptides and methods of use thereof
IL261402A (en) T-cell modulatory multimeric polypeptides and methods of use thereof
IL290635A (en) T-cell modulatory polypeptides and methods of use thereof
IL287192A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
IL280102A (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
IL280922A (en) Anti-her2 polypeptides and methods of use thereof
IL282250A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
IL281505A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
PT3733130T (en) Cardiac valve prosthesis and stent thereof
IL280103A (en) Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
IL283782A (en) Anellosomes and methods of use
IL280808A (en) Ox40-binding polypeptides and uses thereof
IL273847A (en) Bicyclic sulfones and sulfoxides and methods of use thereof
IL274433A (en) Fulvestrant formulations and methods of their use
EP3814487A4 (en) Structure of the human cgas-dna complex and uses thereof
SG11202004529XA (en) Transformed human cell and use thereof
IL276792A (en) Inhaler and methods of use thereof